28515448|t|Involvement Of Vascular Aldosterone Synthase In Phosphate - Induced Osteogenic Transformation Of Vascular Smooth Muscle Cells
28515448|a|Vascular calcification resulting from hyperphosphatemia is a major determinant of mortality in chronic kidney disease (CKD). Vascular calcification is driven by aldosterone -sensitive osteogenic transformation of vascular smooth muscle cells (VSMCs). We show that even in absence of exogenous aldosterone, silencing and pharmacological inhibition (spironolactone, eplerenone) of the mineralocorticoid receptor (MR) ameliorated phosphate - induced osteo- / chondrogenic transformation of primary human aortic smooth muscle cells (HAoSMCs). High phosphate concentrations up-regulated aldosterone synthase (CYP11B2) expression in HAoSMCs. Silencing and deficiency of CYP11B2 in VSMCs ameliorated phosphate - induced osteogenic reprogramming and calcification. Phosphate treatment was followed by nuclear export of APEX1, a CYP11B2 transcriptional repressor. APEX1 silencing up-regulated CYP11B2 expression and stimulated osteo- / chondrogenic transformation. APEX1 overexpression blunted the phosphate - induced osteo- / chondrogenic transformation and calcification of HAoSMCs. Cyp11b2 expression was higher in aortic tissue of hyperphosphatemic klotho-hypomorphic (kl/kl) mice than in wild-type mice. In adrenalectomized kl/kl mice, spironolactone treatment still significantly ameliorated aortic osteoinductive reprogramming. Our findings suggest that VSMCs express aldosterone synthase, which is up-regulated by phosphate - induced disruption of APEX1 -dependent gene suppression. Vascular CYP11B2 may contribute to stimulation of VSMCs osteo- / chondrogenic transformation during hyperphosphatemia.
28515448	0	11	Involvement	T169	C1314939
28515448	15	23	Vascular	T023	C0005847
28515448	24	44	Aldosterone Synthase	T116,T126	C0075233
28515448	48	57	Phosphate	T121,T197	C1601799
28515448	60	67	Induced	T169	C0205263
28515448	68	93	Osteogenic Transformation	T033	C0243095
28515448	97	105	Vascular	T023	C0005847
28515448	106	125	Smooth Muscle Cells	T025	C1135918
28515448	126	148	Vascular calcification	T046	C0342649
28515448	164	181	hyperphosphatemia	T047	C0085681
28515448	208	217	mortality	T081	C0178686
28515448	221	243	chronic kidney disease	T047	C1561643
28515448	245	248	CKD	T047	C1561643
28515448	251	273	Vascular calcification	T046	C0342649
28515448	287	298	aldosterone	T109,T121,T125	C0002006
28515448	310	335	osteogenic transformation	T033	C0243095
28515448	339	347	vascular	T023	C0005847
28515448	348	367	smooth muscle cells	T025	C1135918
28515448	369	374	VSMCs	T025	C1135918
28515448	398	405	absence	T169	C0332197
28515448	409	418	exogenous	T169	C0205228
28515448	419	430	aldosterone	T109,T121,T125	C0002006
28515448	432	441	silencing	T044	C1148560
28515448	446	472	pharmacological inhibition	T044	C1148560
28515448	474	488	spironolactone	T109,T121	C0037982
28515448	490	500	eplerenone	T109,T121	C0961485
28515448	509	535	mineralocorticoid receptor	T116,T192	C0066563
28515448	537	539	MR	T116,T192	C0066563
28515448	553	562	phosphate	T121,T197	C1601799
28515448	565	572	induced	T169	C0205263
28515448	573	579	osteo-	T033	C0243095
28515448	582	609	chondrogenic transformation	T033	C0243095
28515448	613	620	primary	T080	C0205225
28515448	621	626	human	T016	C0086418
28515448	627	633	aortic	T023	C0003483
28515448	634	653	smooth muscle cells	T025	C1135918
28515448	655	662	HAoSMCs	T025	C1135918
28515448	670	679	phosphate	T121,T197	C1601799
28515448	680	694	concentrations	T081	C0392762
28515448	695	707	up-regulated	T044	C0041904
28515448	708	728	aldosterone synthase	T116,T126	C0075233
28515448	730	737	CYP11B2	T116,T126	C1527416
28515448	739	749	expression	T045	C1171362
28515448	753	760	HAoSMCs	T025	C1135918
28515448	762	771	Silencing	T044	C1148560
28515448	776	786	deficiency	T047	C0033626
28515448	790	797	CYP11B2	T116,T126	C1527416
28515448	801	806	VSMCs	T025	C1135918
28515448	819	828	phosphate	T121,T197	C1601799
28515448	831	838	induced	T169	C0205263
28515448	839	863	osteogenic reprogramming	T042	C1254358
28515448	868	881	calcification	T042	C1533591
28515448	883	892	Phosphate	T121,T197	C1601799
28515448	893	902	treatment	T169	C1522326
28515448	919	933	nuclear export	T043	C0887840
28515448	937	942	APEX1	T116,T126	C0140145
28515448	946	953	CYP11B2	T028	C1413857
28515448	954	979	transcriptional repressor	T116,T123	C1336789
28515448	981	986	APEX1	T116,T126	C0140145
28515448	987	996	silencing	T044	C1148560
28515448	997	1009	up-regulated	T044	C0041904
28515448	1010	1017	CYP11B2	T028	C1413857
28515448	1018	1028	expression	T045	C0017262
28515448	1044	1050	osteo-	T033	C0243095
28515448	1053	1080	chondrogenic transformation	T033	C0243095
28515448	1082	1087	APEX1	T116,T126	C0140145
28515448	1088	1102	overexpression	T045	C1514559
28515448	1115	1124	phosphate	T121,T197	C1601799
28515448	1127	1134	induced	T169	C0205263
28515448	1135	1141	osteo-	T033	C0243095
28515448	1144	1171	chondrogenic transformation	T033	C0243095
28515448	1176	1189	calcification	T042	C1533591
28515448	1193	1200	HAoSMCs	T025	C1135918
28515448	1202	1209	Cyp11b2	T028	C1413857
28515448	1210	1220	expression	T045	C0017262
28515448	1235	1241	aortic	T023	C0003483
28515448	1242	1248	tissue	T024	C0040300
28515448	1252	1269	hyperphosphatemic	T047	C0085681
28515448	1270	1301	klotho-hypomorphic (kl/kl) mice	T015	C0025929
28515448	1310	1319	wild-type	T028	C1883559
28515448	1320	1324	mice	T015	C0025929
28515448	1329	1356	adrenalectomized kl/kl mice	T015	C0025929
28515448	1358	1372	spironolactone	T109,T121	C0037982
28515448	1373	1382	treatment	T169	C1522326
28515448	1415	1421	aortic	T023	C0003483
28515448	1422	1450	osteoinductive reprogramming	T042	C1254358
28515448	1456	1464	findings	T169	C2607943
28515448	1478	1483	VSMCs	T025	C1135918
28515448	1492	1512	aldosterone synthase	T116,T126	C0075233
28515448	1523	1535	up-regulated	T044	C0041904
28515448	1539	1548	phosphate	T121,T197	C1601799
28515448	1551	1558	induced	T169	C0205263
28515448	1559	1569	disruption	T169	C0332453
28515448	1573	1578	APEX1	T116,T126	C0140145
28515448	1590	1606	gene suppression	T045	C0038855
28515448	1608	1616	Vascular	T023	C0005847
28515448	1617	1624	CYP11B2	T116,T126	C1527416
28515448	1658	1663	VSMCs	T025	C1135918
28515448	1664	1670	osteo-	T033	C0243095
28515448	1673	1700	chondrogenic transformation	T033	C0243095
28515448	1708	1725	hyperphosphatemia	T047	C0085681